18 December 2013 
EMA/CHMP/804118/2013 
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Pradaxa 
dabigatran etexilate  
On 18 December 2013, the Committee for Medicinal Products for Human Use (CHMP) adopted a 
positive opinion recommending a variation to the terms of the marketing authorisation for the 
medicinal product Pradaxa. The marketing authorisation holder for this medicinal product is Boehringer 
Ingelheim International GmbH. They may request a re examination of the CHMP opinion, provided that 
they notify the European Medicines Agency in writing of their intention within 15 days of receipt of the 
opinion. 
The CHMP adopted the removal of a contraindication as follows: 
• 
Concomitant treatment with systemic ketoconazole, cyclosporine, itraconazole, tacrolimus 
and dronedarone (see section 4.5) 
Detailed conditions for the use of this product will be described in the updated summary of product 
characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after the variation to the 
marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 
within 44 days (Type II variations) and 67 days (Annex II applications) from adoption of the opinion. 
7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom 
Telephone  +44 (0)20 7418 8400  Facsimile +44 (0)20 7418 8613 
E-mail info@ema.europa.eu  Website www.ema.europa.eu 
An agency of the European Union   
© European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
  
 
 
 
                                                
